Pharming Group Financials

PHAR Stock  USD 10.01  0.36  3.73%   
Based on the analysis of Pharming Group's profitability, liquidity, and operating efficiency, Pharming Group NV is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.
  

Pharming Group Stock Summary

Pharming Group competes with Genenta Science, Opthea, Mineralys Therapeutics,, Anebulo Pharmaceuticals, and Janux Therapeutics. Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Pharming Group operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 277 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS71716E1055
CUSIP71716E105
LocationNetherlands
Business AddressDarwinweg 24, Leiden,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.pharming.com
Phone31 71 524 7400
CurrencyUSD - US Dollar

Pharming Group Key Financial Ratios

Pharming Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Pharming Group's current stock value. Our valuation model uses many indicators to compare Pharming Group value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharming Group competition to find correlations between indicators driving Pharming Group's intrinsic value. More Info.
Pharming Group NV is considered to be number one stock in return on equity category among its peers. It is regarded second in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Pharming Group by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Pharming Group NV Systematic Risk

Pharming Group's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Pharming Group volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Pharming Group NV correlated with the market. If Beta is less than 0 Pharming Group generally moves in the opposite direction as compared to the market. If Pharming Group Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Pharming Group NV is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Pharming Group is generally in the same direction as the market. If Beta > 1 Pharming Group moves generally in the same direction as, but more than the movement of the benchmark.

Steps to analyze company Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Pharming Group is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Pharming has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if Pharming Group's financials are consistent with your investment objective using the following steps:
  • Review Pharming Group's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand Pharming Group's liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare Pharming Group's financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Pharming Group's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

Pharming Group January 22, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Pharming Group help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Pharming Group NV. We use our internally-developed statistical techniques to arrive at the intrinsic value of Pharming Group NV based on widely used predictive technical indicators. In general, we focus on analyzing Pharming Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Pharming Group's daily price indicators and compare them against related drivers.

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.